Literature DB >> 3345041

Nasal provocation with bradykinin induces symptoms of rhinitis and a sore throat.

D Proud1, C J Reynolds, S Lacapra, A Kagey-Sobotka, L M Lichtenstein, R M Naclerio.   

Abstract

Kinins are generated in nasal secretions during allergic reactions and during induced rhinovirus colds. To determine if kinins may contribute to the symptomatology of these inflammatory reactions, 8 subjects were challenged with increasing doses of bradykinin or with placebo. Levels of albumin, histamine, and N-alpha-tosyl-L-arginine methyl ester (TAME)-esterase were measured in nasal lavages, and symptom scores were noted. No symptoms or increases in mediators or protein were observed after placebo challenge. Symptom scores increased in a dose-dependent manner, however, in response to bradykinin challenge. Increased symptoms were associated with significant increases in albumin and TAME-esterase activity, but no increases in histamine were observed. Nasal conductance measurements confirmed that bradykinin induces dose-dependent unilateral obstruction in the challenged nostril. Other common symptoms were rhinorrhea and, of particular relevance to rhinovirus infections, a persistent sore throat. We conclude that bradykinin causes increased vascular permeability and rhinitis, which are independent of mast cell mediator release. Kinins may, therefore, contribute to the symptomatology of inflammatory reactions of the upper airways, including the common cold.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3345041     DOI: 10.1164/ajrccm/137.3.613

Source DB:  PubMed          Journal:  Am Rev Respir Dis        ISSN: 0003-0805


  42 in total

1.  A competitive kinin receptor antagonist, [DArg0, Hyp3, DPhe7]-bradykinin, does not affect the response to nasal provocation with bradykinin.

Authors:  J A Pongracic; R M Naclerio; C J Reynolds; D Proud
Journal:  Br J Clin Pharmacol       Date:  1991-03       Impact factor: 4.335

Review 2.  New insights into protease-activated receptor 4 signaling pathways in the pathogenesis of inflammation and neuropathic pain: a literature review.

Authors:  Yanju Bao; Yebo Gao; Liping Yang; Xiangying Kong; Honggang Zheng; Wei Hou; Baojin Hua
Journal:  Channels (Austin)       Date:  2015       Impact factor: 2.581

3.  A study of the efficacy of the bradykinin antagonist, NPC 567, in rhinovirus infections in human volunteers.

Authors:  P G Higgins; G I Barrow; D A Tyrrell
Journal:  Antiviral Res       Date:  1990-12       Impact factor: 5.970

Review 4.  Antihistamines and the common cold. A review and critique of the literature.

Authors:  D Luks; M R Anderson
Journal:  J Gen Intern Med       Date:  1996-04       Impact factor: 5.128

5.  Inhibition of bradykinin-induced bronchoconstriction in the guinea-pig by a synthetic B2 receptor antagonist.

Authors:  L S Jin; E Seeds; C P Page; M Schachter
Journal:  Br J Pharmacol       Date:  1989-06       Impact factor: 8.739

6.  Effect of nedocromil sodium on allergen-, PAF-, histamine- and bradykinin-induced airways vasodilatation and pulmonary obstruction in the pig.

Authors:  K Alving; R Matran; J M Lundberg
Journal:  Br J Pharmacol       Date:  1991-10       Impact factor: 8.739

7.  A study of the action of bradykinin and bradykinin analogues in the human nasal airway.

Authors:  C E Austin; J C Foreman
Journal:  J Physiol       Date:  1994-07-15       Impact factor: 5.182

8.  Attenuation of human nasal airway responses to bradykinin and histamine by inhibitors of nitric oxide synthase.

Authors:  J W Dear; S Ghali; J C Foreman
Journal:  Br J Pharmacol       Date:  1996-07       Impact factor: 8.739

9.  Formoterol and salbutamol inhibit bradykinin- and histamine-induced airway microvascular leakage in guinea-pig.

Authors:  C Advenier; Y Qian; J D Koune; M Molimard; M L Candenas; E Naline
Journal:  Br J Pharmacol       Date:  1992-04       Impact factor: 8.739

10.  Immunohistochemical localization of the bradykinin B1 and B2 receptors in human nasal mucosa.

Authors:  Hideaki Shirasaki; Etsuko Kanaizumi; Tetsuo Himi
Journal:  Mediators Inflamm       Date:  2009-04-23       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.